SBP Provides a Business Update and Files Report for Q2 2018

  • First Patients Enrolled in Front-Line Combination Study of SBP-101 with Gemcitabine and nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
  • Additional Funds Raised during Q2

View/download press release »